Login / Signup

Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.

Uta KiltzXenofon BaraliakosJan Brandt-JürgensUlf WagnerSebastian LiebChristian SiederChristian MannJüergen Braun
Published in: Therapeutic advances in musculoskeletal disease (2024)
ClinicalTrials.gov; NCT02763046, EudraCT 2015-004575-74.
Keyphrases
  • ankylosing spondylitis
  • disease activity
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • robot assisted